About QIAGEN
QIAGEN N.V., a Netherlands holding company, is the leading provider of innovative sample and assay technologies and products. QIAGEN’s products are considered standards in areas such as pre-analytical sample preparation and assay solutions for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions. The company’s products are sold to academic research markets, leading pharmaceutical and biotechnology companies, applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) and molecular diagnostics laboratories. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries; the company employs more than
2,600 people worldwide. Further information about QIAGEN can be found at www.qiagen.com. Further information about HPV DNA testing can be
found at www.theHPVtest.com.
(1) The hc2 High Risk HPV test has been approved by the Food and Drug Administration for the follow-up evaluation of women with ASC-US
(inconclusive) cytology and for use as an adjunctive test combined with the Pap to screen women age 30 years and older.
(2) This information is provided as a summary of several clinical studies. The use of the Hybrid Capture(R) High-Risk HPV DNA Test as a stand-alone screen for cervical cancer has not been approved by the U.S.
Food and Drug Administration.
SOURCE QIAGEN N.V.
10/18/2007
CONTACT: Pam Rasmussen, Vice President, Communications, Digene, A QIAGEN Company, +1-240-506-0766, Pamela.Rasmussen@digene.com; or Jennifer Garratt, Burson-Marsteller UK, +44-7979-603236, jennifer.garratt@bm.com
Web site: www.qiagen.com
(QGEN)
NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk
Filed under Buzz, Cervical Cancer, HIV | AIDS, std testing |2 Responses to “About QIAGEN”
Leave a Reply
[...] About QIAGEN [...]
[...] About QIAGEN [...]